吉林秉责律师事务所 关于通化东宝药业股份有限公司 二 0 二四年年度股东大会的法律意见书 网络投票时间：网络投票起止时间：自 2025 年 5 月 21 日 至 2025 年 5 月 21 日。采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 经本所律师审查，公司本次股东大会召开的时间、地点符合公告通知的内容。 公司本次股东大会召集、召开的程序符合《公司法》、《证券法》、《股东会规 则》、《上海证券交易所上市公司股东大会网络投票实施细则》等有关法律、法 规、规范性文件和《公司章程》的有关规定。 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共 和国公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股 东会规则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股 份有限公司（以下简 ...

Core Viewpoint - The company is actively adjusting its supply chain in response to the 20% tariff challenge and is focusing on high-barrier, high-margin products to maintain its competitive edge in the pharmaceutical industry [2][4]. Company Overview - The company, Jianyou Co., Ltd., is a pharmaceutical enterprise engaged in drug research, production, and sales, with a diverse product pipeline including cardiovascular, neurological, anesthetics, anti-tumor preparations, and high-value sterile injectables [4]. Financial Performance - In Q1 2025, the company reported a main revenue of 885 million yuan, a year-on-year decrease of 11.85% - The net profit attributable to shareholders was 84.71 million yuan, down 52.19% year-on-year - The net profit after deducting non-recurring gains and losses was 75.32 million yuan, a decline of 56.05% - The debt ratio stood at 26.38%, with investment income of 11.13 million yuan and financial expenses of 21.80 million yuan - The gross profit margin was 34.41% [4]. Product Development - The company’s biosimilar drugs are entering a harvest period, with liraglutide expected to receive FDA approval in April 2024, making the company the third globally to enter the market - Sales of adalimumab (Yusimry) have already surpassed 70 million yuan - Collaborations with Tonghua Dongbao and Double Star Pharmaceutical are progressing well, with a focus on insulin and paclitaxel products [4]. Market Strategy - The company views the U.S. market as a significant revenue source and plans to expand into Europe, the Middle East, and Central and South America by 2030, aiming to become a global enterprise [2][4]. Analyst Ratings - In the last 90 days, 9 institutions have given buy ratings for the stock, with an average target price of 19.21 yuan [5]. Profit Forecast - Detailed profit forecasts indicate expected net profits for 2025 ranging from 10.25 billion yuan to 12.18 billion yuan, with projections for 2026 and 2027 also showing growth [7]. Financing Activity - In the past three months, the stock has seen a net inflow of 52.81 million yuan in financing, with an increase in financing balance, while the net inflow of short selling was 953,600 yuan [7].

5月20日，A股市场整体上涨。 截至收盘，上证指数收报3380.48点，上涨0.38%；深证成指收报10249.17点，上涨0.77%；创业板指 收报2048.46点，上涨0.77%。两市合计成交11696.81亿元，较上一交易日增加832.34亿元。 1. 两市主力资金净流出近20亿元 3.传媒等行业实现净流入 | | | 资金净流入居前的行业 | | | --- | --- | --- | --- | | 行业 | 涨跌幅 | 净流入资金 (亿元) | 资金流入较多个股 | | 传媒 | 1.93% | 39.80 | 汤姆猫 | | 医药生物 | 1.88% | 37.70 | 药明康德 | | 公用事业 | 1. 29% | 27. 53 | 国电电力 | | 食品饮料 | 1. 75% | 16. 06 | 伊利股份 | | 农林牧渔 | 2. 37% | 14. 44 | 回盛生物 | | 行业 | 涨跌幅 | 净流入资金 (亿元) | 资金流出较多个股 | | --- | --- | --- | --- | | 基础化工 | 0. 57% | -43. 37 | 红宝丽 | | 机械设备 | 1 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-034 通化东宝药业股份有限公司 关于 2024 年度和 2025 年第一季度业绩说明会 变更会议召开信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 27 日（星期二） 15:00-16:30 ? 会议召开地点：全景网"投资者关系互动平台"（网址： https://rs.p5w.net/c/600867） ? 会议召开方式：网络在线问答互动 公司将召开 2024 年度和 2025 年第一季度业绩说明会暨参加由吉林省证券业 协会、深圳市全景网络有限公司共同举办的"2025 年吉林辖区上市公司投资者 网上集体接待日活动"，本次投资者说明会以网络互动形式召开，公司将针对 展战略、经营状况等与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 27 日 15:00-16:30 （二）会议召开地点：全景网" ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-034 通化东宝药业股份有限公司 关于 2024 年度和 2025 年第一季度业绩说明会 变更会议召开信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日（星期二） 15:00-16:30 会 议 召 开 地 点 ： 全 景 网 " 投 资 者 关 系 互 动 平 台 " （ 网 址 ： https://rs.p5w.net/c/600867） （三）会议召开方式：网络在线问答互动 三、参加人员 会议召开方式：网络在线问答互动 通化东宝药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日 在上海证券交易所网站（www.sse.com.cn）披露了《通化东宝关于召开 2024 年 度和 2025 年第一季度业绩说明会的公告》（公告编号：2025-030）。因相关工 作时间安排，现变更本次业绩说明会的召开时间、地点等信息，时间由 2025 年 5 月 26 日变更为 2025 年 ...

Group 1 - The core viewpoint of the article highlights the strategic financing and development plans of Junhe Alliance Biopharmaceuticals, which aims to enhance its product pipeline in serious and consumer healthcare sectors [1][3] - Junhe Alliance was founded in November 2020 and is based in Hangzhou, Zhejiang Province, focusing on the development of innovative recombinant protein drugs and synthetic biology [3] - The company has a diverse product pipeline including recombinant type I and III human collagen, recombinant type A botulinum toxin, recombinant human growth hormone, and long-acting growth hormone, with a strong emphasis on both serious and consumer healthcare [3] Group 2 - Junhe Alliance recently completed a strategic financing round of several tens of millions, led by Shiyao Guofang's pilot fund, with the funds aimed at advancing clinical progress and market promotion of its product pipeline [1] - The company has a history of financing rounds, including nearly 200 million in A1 round financing in October 2022, nearly 100 million in A+ round financing in January 2023, and over 200 million in B+ round financing in September 2024 [5]

7月24日，创新药盘中崛起，截止发稿，A股方面，三生国健、百利天恒涨超7%，海思科、诺诚健华、仙琚制药涨超4%，科伦制药、通化东宝等跟涨。 | 代码 名称 | 涨幅 | 消费 | 现价 | | --- | --- | --- | --- | | 000908 景峰医药 | +10.12% | +0.26 | 2.83 | | 688336 三生国健 | +7.66% | +1.38 | 19.26 | | 688506 自利大恒-U | +6.80% | +5.51 | 86.51 | | 688305 海外交 - U | +5.86% | +2.84 | 51.29 | | 688658 倪康药业 | +4.63% | +0.80 | 18.09 | | 002653 海器科 | +4.63% | +1.02 | 23.07 | | 688428 诺诚健华-U | +4.17% | +0.48 | 11.99 | | 603567 珍宝岛 | +4.09% | +0.57 | 14.26 | | 002332 仙琚制药 | +4.01% | +0.50 | 12.97 | | 600276 恒瑞 名 | + ...

61只个股今日获机构买入型评级，电连技术最新评级被调高，12股机构首次关注。 证券时报·数据宝统计显示，今日机构研报共发布62条买入型评级记录，共涉及61只个股。赛轮轮胎关 注度最高，共获2次机构买入型评级记录。 今日获机构买入型评级个股中，共有13条评级记录中对相关个股给出了未来目标价。以公布的预测目标 价与最新收盘价进行对比显示，共有11股上涨空间超20%，北新建材上涨空间最高，5月15日国泰海通 预计公司目标价为49.00元，上涨空间达69.96%，上涨空间较高的个股还有长城汽车、通化东宝等，上 涨空间分别为68.46%、45.66%。 机构今日买入型评级个股 | 代码 | 简称 | 买入评级家数 | 今日涨跌幅（%） | 动态市盈率（倍） | 行业 | | --- | --- | --- | --- | --- | --- | | 601058 | 赛轮轮胎 | 2 | -1.55 | 10.05 | 汽车 | | 601633 | 长城汽车 | 1 | -0.42 | 28.79 | 汽车 | | 603297 | 永新光学 | 1 | -1.97 | 43.04 | 电子 | | 603368 | ...

Policy Developments - The National Medical Products Administration (NMPA) emphasizes the need for comprehensive drug regulation reform to enhance drug safety and support high-quality development in the pharmaceutical industry [2] Drug and Device Approvals - Zai Lab's new drug application for JAK inhibitor, Tofacitinib, for treating severe alopecia areata has been accepted by the NMPA, marking its second indication for this drug [4] - Tonghua Dongbao's insulin injection has received marketing approval in Nicaragua, expanding its overseas sales potential [5] - BeiGene's new indication application for its BCL2 inhibitor, Sotorasib, for treating mantle cell lymphoma has been accepted by the NMPA [6] - Yilian Biopharma's antibody-drug conjugate targeting VEGF has received clinical trial approval in the U.S. [7] - Zhengda Tianqing's combination therapy for advanced hepatocellular carcinoma has shown positive results in a Phase III trial, with plans for a market application in November 2024 [8] - Rongchang Biopharma's clinical trial application for its ADC molecule RC278 has been accepted by the NMPA [9][10] Capital Markets - Easternova Biotechnology has submitted its IPO application to the Hong Kong Stock Exchange, focusing on regenerative medical materials [12] - China National Pharmaceutical Group plans to acquire 100% of Jinsui Technology for 302 million yuan, enhancing its e-commerce operations in health products [13] Industry Developments - Suzhou Industrial Park has launched a plan to accelerate the development of the biopharmaceutical and health industry, focusing on innovation and enterprise growth [15] - Ganli Pharmaceutical has signed a cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese pharmaceutical company to enter Brazil's PDP program [16]

Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]